FMS logo

FRESENIUS MEDICAL CARE-ADR

FMSNYSE
πŸ† #729 by market capEarnings Nov 3 Β· PreUS Equity
$22.62β–² $0.13 (+0.58%)
Pre-market Β· at close
πŸ””
Track FMS
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 0.6%
7dβ–² 1.8%
14dβ–² 2.3%
30dβ–² 1.6%
ytdβ–Ό 5.1%
1yβ–Ό 15.9%
🏦Market Cap
$12.06B
Mid Cap
πŸ“ˆRevenue Growth (YoY)
1.5%
Slowing
πŸ“ŠGross Margin
26.4%
Moderate
πŸ’΅FCF Margin
9.2%
Moderate
βš–οΈP/S Ratio
0.6x
Cheap
Otter Score
64
Fair

Trading Snapshot

Day Range
$22.47 – $22.70
52-Week Range
$20.02 – $27.40
Volume (shares)
79,854
Avg Volume (shares)
β€”
Shares Outstanding
533.1M
Next Earnings
2026-11-03

Fundamentals Snapshot

Annual Revenue
$19.63B
Last Q Revenue
$4.86B
P/E Ratio
12.3
P/S Ratio
0.6x
EPS (TTM)
$1.75
Dividend Yield
3.65%
Dilution (1yr)
βˆ’51.3%
FMS logo

FRESENIUS MEDICAL CARE-ADR

FMS
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$19.6Bβ–² +1.5% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
25.6%β–² +4.2% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$1.8Bβ–² +24.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$1.7Bβ–² +0.5% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
571.8Mβ–Ό βˆ’51.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$9.2Bβ–² +$628M YoY
StockOtter Β· stockotter.space

About FRESENIUS MEDICAL CARE-ADR

Fresenius Medical Care AG & Co. KGaA specializes in comprehensive kidney dialysis treatment and associated services, operating across Germany, North America, and numerous international territories. Through an extensive network of outpatient clinics, it delivers essential dialysis therapy along with laboratory and diagnostic support. For home-based care, the company supplies necessary equipment, provides comprehensive training, and offers ongoing patient assistance, including clinical oversight and coordinating supply deliveries directly to patients. In the United States, Fresenius Medical Care also contracts with hospitals to provide vital dialysis interventions for hospitalized individuals suffering from end-stage renal disease (ESRD) and acute kidney failure. Beyond services, it is a prominent developer, manufacturer, and distributor of a broad range of dialysis products. This portfolio encompasses polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers and solutions, concentrates, bloodlines, renal pharmaceuticals, and water treatment systems. Additionally, the company produces non-dialysis medical devices, including acute cardiopulmonary and apheresis products. Its pharmaceutical division focuses on developing, acquiring, and in-licensing specialized renal medications, distributing these essential drugs and supplies to both individual patients' homes and dialysis centers. The company also extends its medical offerings to include a variety of specialized services such as vascular, cardiovascular, and endovascular care, operating ambulatory surgery centers for vascular procedures, and providing physician services in nephrology and cardiology. Products are sold directly to dialysis clinics, hospitals, and specialized treatment centers, complemented by sales through local teams, independent distributors, dealers, and agents. By February 23, 2022, Fresenius Medical Care managed an impressive network of 4,171 outpatient dialysis clinics across roughly 150 countries. Established in 1996, the company maintains its headquarters in Bad Homburg, Germany.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
64/100

Analyst Ratings

β“˜
Consensus
Hold
29 analysts
Strong Buy3
Buy2
Hold12
Sell10
Strong Sell2
Ratings as of Oct 2026

Latest News & Updates

News unavailable.